Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data.
(2013) Alimentary Pharmacology and Therapeutics — Vol. 38, n° 4, p. 397-406 (2013)
Files
TemmermanFetalAlimentPharmacoltHER201338397-406.pdf
Restricted Access - Adobe PDF
- 345.12 KB
Details
- Authors
- Abstract
- Both LAN 90 mg and LAN 120 mg reduce liver volume. LAN 90 mg has less side effects. This suggests that in case of intolerance to LAN 120 mg, a dose reduction to LAN 90 mg is meaningful.
- Affiliations
Citations
Temmerman, F., Gevers, T., Ho, T. A., Vanslembrouck, R., Coudyzer, W., van Pelt, J., Bammens, B., PIRSON, Y., Drenth, J. P., & Nevens, F. (2013). Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Alimentary Pharmacology and Therapeutics, 38(4), 397-406. https://doi.org/10.1111/apt.12384 (Original work published 2013)